951753-38-1

Basic information

• Product Name: 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-bitrideuteratedmethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
• Synonyms: 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-bitrideuteratedmethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
• CAS NO: 951753-38-1
• Molecular Weight: 465.431
• Mol File: 951753-38-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-bitrideuteratedmethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-bitrideuteratedmethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(951753-38-1)
• EPA Substance Registry System: 4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-bitrideuteratedmethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide(951753-38-1)

Safety Data

• Hazardous Substances Data: 951753-38-1(Hazardous Substances Data)

Upstream product

• 22245-83-6 3-(trifluoromethyl)pyridin-2-ol 
• 99368-66-8 2-hydroxyl-5-nitro-3-(trifluoromethyl)pyridine 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 573762-62-6 5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile 
• 463-71-8 thiophosgene 
• 573762-57-9 2-cyano-3-(trifluoromethyl)-5-nitropyridine 

Relevant articles and documents

Prostatic cancer treatment medicine

The invention relates to a compound with a prostatic cancer treatment function and nontoxic pharmaceutically acceptable salt of the compound. The structure of the compound is as shown in a formula I,wherein X is C or N, R1 is alkyl of C1-C3 or halogen substituted alkyl, R2 is alkyl of C1-C3 and halogen substituted alkyl or halogen, R3 and R4 are independently selected from H, alkyl and substituted alkyl, and R3 and R4 are connected to form cycloalkyl. The compound has high inhibiting effects on in-situ prostate cancer and transfer of the prostate cancer, and eclamptogenic side effects are lower.